Fig. 1: Gene expression profiling of mature DC from HD and melanoma patients. | Nature Communications

Fig. 1: Gene expression profiling of mature DC from HD and melanoma patients.

From: Immuno-metabolic dendritic cell vaccine signatures associate with overall survival in vaccinated melanoma patients

Fig. 1: Gene expression profiling of mature DC from HD and melanoma patients.The alternative text for this image may have been generated using AI.

A Conceptual overview of ex vivo mDC culture conditions with indicated time points used for profiling methods used in this study including microarray, Seahorse assay, culture supernatants Luminex assay, glucose and lactate measurements (Gluc/Lact), SCENITH and scMEP. B Volcano plots show differential gene expression at false discovery rate threshold of 5% by fold change (logFC) and adj.p-value (−log10(adj.p)) comparing changes between mDC vs iDC for HD (magenta/blue, n = 4) and melanoma (green/black, n = 35) patients. Dark gray dots denote non-significant genes, orange dots denote significant genes with fold change ≤2 and magenta dots indicate genes with fold change ≥2 and adj.p value ≤ 0.05. Labeled are top 15 significant genes. C Summary of significantly upregulated and downregulated pathways (adj.p < 0.05) with overlapping gene sets identified by GSEA/MSigDB analysis between mDC vs iDC from HD (magenta/blue, n = 4) and melanoma (green/black, n = 35) patients. D Summary of significantly (adj.p < 0.05) different GSEA/MSigDB pathways between good (PR/SD/NED1, n = 13) and bad (PD/NED2, n = 17) outcome groups in mature mDC. The color-coding scale denotes magnitude of normalized enrichment score (NES) for each pathway with red and blue colors corresponding to enrichment in good and bad outcome mDC groups, respectively.

Back to article page